--- title: "PepGen (PEPG) news: class action and offering" url: "https://aibio.space/companies/pepgen/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PEPG class action and offering news: PepGen reports its securities class action and shareholder demand are over. PepGen Inc. (NASDAQ: PEPG), United States." --- PEPG PepGen Inc. NASDAQ · United States # PepGen (PEPG) news PEPG class action and offering news Legal · 2026-08-06 ## [PepGen reports its securities class action and shareholder demand are over](https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/) The 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly. ## Latest PepGen news 1. 2025-09-24 Financings [PepGen prices $100,000,000 public offering of 31,250,000 shares at $3.200](https://aibio.space/news/pepgen-prices-100-000-000-public-offering-31-250-000-shares-3-200/) PepGen priced 31,250,000 shares at $3.200 for gross proceeds of $100,000,000, a price above the $2.66 close the filings report for September 24, 2025. The company says the proceeds plus its existing cash will not be enough to finish development of any product candidate. ## PepGen at a glance - **Ticker**: PEPG - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $117.2 million ### Related companies - [Cell Source](https://aibio.space/companies/cell-source/) OTC: CLCS - [Natera](https://aibio.space/companies/natera/) NASDAQ: NTRA - [Abpro Holdings](https://aibio.space/companies/abpro/) OTC: ABPO - [Arvinas](https://aibio.space/companies/arvinas/) NASDAQ: ARVN - [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) NASDAQ: MNPR - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD ### Also on NASDAQ - [Inogen](https://aibio.space/companies/inogen/) INGN - [TREACE MEDICAL CONCEPTS, INC.](https://aibio.space/companies/treace-medical-concepts/) TMCI - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) BMRN - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) SNOA - [CYPHERPUNK TECHNOLOGIES INC.](https://aibio.space/companies/cypherpunk-technologies/) CYPH - [ProMIS Neurosciences](https://aibio.space/companies/promis-neurosciences/) PMN ## PepGen annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$71.0 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | [$76.5 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | | Net income (loss) | [-$89.7 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | [-$90.0 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | | Cash from operations | [-$81.6 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | [-$82.4 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | | Cash and equivalents | [$60.5 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526336754/) | [$49.4 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | | Short-term investments | [$87.9 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526336754/) | [$70.8 million](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.8 million, plus short-term investments of $94.5 million, $117.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PepGen Is there a class action against PepGen? Our latest story on this, dated Aug 6, 2026: "PepGen reports its securities class action and shareholder demand are over". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/). Has PepGen raised money recently? Our latest story on this, dated Sep 24, 2025: "PepGen prices $100,000,000 public offering of 31,250,000 shares at $3.200". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pepgen-prices-100-000-000-public-offering-31-250-000-shares-3-200/). What is the ticker symbol of PepGen? PepGen Inc. trades under the ticker PEPG on NASDAQ. Where is PepGen listed? PepGen Inc. is listed on NASDAQ. What is the SEC CIK of PepGen? The SEC Central Index Key (CIK) for PepGen Inc. is 1835597. Its filings are on SEC EDGAR. How many shares does PepGen have outstanding? 69,259,517 shares as of 2026-08-02, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is PepGen listed under? Our directory records PepGen Inc. under United States. What does PepGen do? Our directory classifies PepGen Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of PepGen? The ISIN recorded for PepGen Inc. is US7133171055. Does aibio.space cover PepGen? aibio.space lists PepGen Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is PepGen incorporated? SEC records list its state or country of incorporation as DE. Is PepGen profitable? PepGen Inc. reported a net loss of $89.7 million for the fiscal year ended Dec 31, 2025, and used $81.6 million of cash in operations, per its annual report to the SEC. How much does PepGen spend on research and development? $71.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does PepGen have? $117.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest PepGen (PEPG) stock news? Our latest story on PepGen, dated Aug 6, 2026: "PepGen reports its securities class action and shareholder demand are over". The 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly. [Source](https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/). ## Investor discussion: PepGen Members talk about PepGen (PEPG). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PepGen, newest first. Each line links the filing it comes from. 1. 2026-05-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm) 2. 2025-09-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1835597/000119312525215540/d25212d424b5.htm) 3. 2025-08-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1835597/000119312525174979/pepg-20250630.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PEPG on TradingView](https://www.tradingview.com/symbols/NASDAQ-PEPG/). ## SEC filings and registration - **SEC name**: PepGen Inc. - **CIK**: 1835597 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PEPG (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210 - **Phone**: 703-456-8000 - **Shares outstanding**: 69,259,517 as of 2026-08-02 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-20260806.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1835597/000119312526336754/pepg-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1835597/000119312526277579/pepg-20260618.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1835597/000119312526233403/d54577d8k.htm) filed 2026-05-21 - [S-3](https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm) filed 2026-05-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/pepg-20260512.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1835597/000119312526219375/pepg-20260331.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1835597/000119312526186927/pepg-20260428.htm) filed 2026-04-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001835597), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PepGen Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PEPG, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PepGen Inc. - **Ticker**: PEPG - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US7133171055 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PEPG/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pepgen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PepGen (PEPG) news: class action and offering", 2026-10-31, https://aibio.space/companies/pepgen/